News
TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive topline results from the TROPION-Breast01 phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback